Compare · AXNX vs DXCM

AXNX vs DXCM

Side-by-side comparison of Axonex AI Group Limited (AXNX) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • AXNX operates in Consumer Discretionary, while DXCM operates in Health Care - the two are in different parts of the market.
  • DXCM is the larger of the two at $33.00B, about 5236.6x AXNX ($6.3M).
  • DXCM has been more active in the news (9 items in the past 4 weeks vs 2 for AXNX).
  • DXCM has more recent analyst coverage (25 ratings vs 21 for AXNX).
MetricAXNXDXCM
Company
Axonex AI Group Limited
DexCom Inc.
Price
-
-
Market cap
$6.3M
$33.00B
1M return
-
+6.10%
1Y return
-
+49.23%
Industry
Business Services
Medical/Dental Instruments
Exchange
NASDAQ
NASDAQ
IPO
2018
2005
News (4w)
2
9
Recent ratings
21
25
AXNX

Axonex AI Group Limited

Axonex AI Group Limited (formerly Mint Incorporation Limited) (NASDAQ: AXNX) is a Hong Kong-based company strategically focused on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider. Through its subsidiary, Axonex AI Limited, and its majority owned subsidiary, Rice Robotics AGI Holding Limited, the Group delivers robot models and robotics solutions, including the FLOKI Minibot M1 and micro-insurance solutions purpose-built for commercial robots. The Group also maintains its established interior design and fit-out works business. Anchored by its ongoing transformation, Axonex AI is focused on AI and robotics as its main growth driving engine.

DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Latest AXNX

Latest DXCM